John DiPersio, MD, PhD

Bone Marrow Transplant Specialist, Medical Oncologist

Primary Academic Title

Virginia E. and Sam J. Golman Endowed Professorship of Medicine, Pathology & Immunology; Professor of Pediatrics; Director, Center for Gene and Cellular Immunotherapy, WashU Medicine

Clinical Expertise

Bone marrow transplantation and leukemia

Research Interest

Molecular biology of cytokine receptor signaling; use and manipulation of mobilized peripheral blood stem cells for autologous and allogeneic transplantation; genetic manipulation of T cells using suicide genes; and targeted gene expression in early hematopoietic stem cells.

Education

1980: MD/PhD, microbiology, University of Rochester, Rochester, N.Y.

Training

1980 - 1984: Intern and resident, internal medicine, University of Texas Southwestern Medical Center, Dallas
1984 - 1987: Fellow, hematology/oncology, University of California, Los Angeles

Board Certification

1984: American Board of Internal Medicine, Internal Medicine
1987: American Board of Internal Medicine, Medical Oncology
1988: American Board of Internal Medicine, Hematology

Selected Research Publications

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Mushtaq MU, DiPersio JF, Azzi J, [...] Muffly LS
Blood 2026

BACH2 regulates T cell lineage state to enhance CAR T cell function.

Chang TC, Heard A, Lattin J, [...] DiPersio JF, [...] Singh N
Nat Immunol 2026

Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma.

Li YD, Giles DA, Huang Y, [...] DiPersio JF, [...] Chheda MG
Nat Commun 2026

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

Pilcher WC, Yao L, Gonzalez-Kozlova E, [...] DiPersio JF, [...] Bhasin M
Nat Cancer 2026

The cancer genome and the birth of precision medicine.

DiPersio JF
Haematologica 2025

Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).

Koehne G, Mushtaq MU, Muffly LS, [...] DiPersio JF
JCO Precis Oncol 2025

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.

Ghobadi A, Aldoss I, Maude SL, [...] DiPersio JF
Blood 2025

Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity.

Thomas R, Ritchey JK, DiPersio JF, Kim MY
Mol Ther 2025

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Arellano ML, Thirman MJ, DiPersio JF, [...] Blachly JS
Blood 2025

Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study.

Frigault MJ, Maziarz RT, Park JH, [...] DiPersio JF
Blood 2025

Clonal hematopoiesis landscape in frequent blood donors.

Karpova D, Huerga Encabo H, Donato E, [...] DiPersio JF, [...] Trumpp A
Blood 2025

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.

Abboud R, Schroeder MA, Rettig MP, [...] DiPersio JF
Blood 2025

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial.

Ghobadi A, Caimi PF, Reese JS, [...] DiPersio J, [...] de Lima M
EClinicalMedicine 2025

Severe acute cutaneous-only graft-versus-host disease after late relapse of chronic myeloid leukemia and ultraviolet B phototherapy.

Beeler JS, Peravali R, Augustin KM, [...] DiPersio JF
Haematologica 2025

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).

Issa GC, Aldoss I, Thirman MJ, DiPersio J, [...] Stein EM
J Clin Oncol 2025

View All Publications

Contact Information

Gary C. Werths Building at Siteman Cancer Center

4500 Forest Park Avenue
Saint Louis, MO 63108

Phone Numbers

Appointments: (314) 747-7222
Toll Free: (800) 600-3606

Request an appointment